South Korea · Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 3.80 trillion. The enterprise value is 3.46 trillion.
| Market Cap | 3.80T |
| Enterprise Value | 3.46T |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 7.09% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | +7.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 35.02% |
| Owned by Institutions (%) | 11.56% |
| Float | 5.57M |
Valuation Ratios
The trailing PE ratio is 21.90 and the forward PE ratio is 22.16. PharmaResearch's PEG ratio is 0.88.
| PE Ratio | 21.90 |
| Forward PE | 22.16 |
| PS Ratio | 6.30 |
| PB Ratio | 4.82 |
| P/TBV Ratio | 5.24 |
| P/FCF Ratio | 27.58 |
| P/OCF Ratio | 21.99 |
| PEG Ratio | 0.88 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.01, with an EV/FCF ratio of 25.11.
| EV / Earnings | 18.65 |
| EV / Sales | 5.74 |
| EV / EBITDA | 14.01 |
| EV / EBIT | 15.03 |
| EV / FCF | 25.11 |
Financial Position
The company has a current ratio of 7.78, with a Debt / Equity ratio of 0.28.
| Current Ratio | 7.78 |
| Quick Ratio | 6.61 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 0.87 |
| Debt / FCF | 1.60 |
| Interest Coverage | 22.76 |
Financial Efficiency
Return on equity (ROE) is 27.34% and return on invested capital (ROIC) is 49.07%.
| Return on Equity (ROE) | 27.34% |
| Return on Assets (ROA) | 14.52% |
| Return on Invested Capital (ROIC) | 49.07% |
| Return on Capital Employed (ROCE) | 23.43% |
| Weighted Average Cost of Capital (WACC) | 6.71% |
| Revenue Per Employee | 1.10B |
| Profits Per Employee | 337.62M |
| Employee Count | 550 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, PharmaResearch has paid 61.66 billion in taxes.
| Income Tax | 61.66B |
| Effective Tax Rate | 24.01% |
Stock Price Statistics
The stock price has decreased by -45.78% in the last 52 weeks. The beta is 0.48, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -45.78% |
| 50-Day Moving Average | 374,540.00 |
| 200-Day Moving Average | 360,440.00 |
| Relative Strength Index (RSI) | 43.08 |
| Average Volume (20 Days) | 135,146 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 603.58 billion and earned 185.69 billion in profits. Earnings per share was 16,711.23.
| Revenue | 603.58B |
| Gross Profit | 469.05B |
| Operating Income | 235.82B |
| Pretax Income | 256.82B |
| Net Income | 185.69B |
| EBITDA | 252.62B |
| EBIT | 235.82B |
| Earnings Per Share (EPS) | 16,711.23 |
Balance Sheet
The company has 595.64 billion in cash and 220.28 billion in debt, with a net cash position of 375.35 billion or 36,127.64 per share.
| Cash & Cash Equivalents | 595.64B |
| Total Debt | 220.28B |
| Net Cash | 375.35B |
| Net Cash Per Share | 36,127.64 |
| Equity (Book Value) | 789.58B |
| Book Value Per Share | 72,540.68 |
| Working Capital | 682.20B |
Cash Flow
In the last 12 months, operating cash flow was 172.89 billion and capital expenditures -35.00 billion, giving a free cash flow of 137.90 billion.
| Operating Cash Flow | 172.89B |
| Capital Expenditures | -35.00B |
| Depreciation & Amortization | 16.80B |
| Net Borrowing | -5.83B |
| Free Cash Flow | 137.90B |
| FCF Per Share | 13,272.43 |
Margins
Gross margin is 77.71%, with operating and profit margins of 39.07% and 30.76%.
| Gross Margin | 77.71% |
| Operating Margin | 39.07% |
| Pretax Margin | 42.55% |
| Profit Margin | 30.76% |
| EBITDA Margin | 41.85% |
| EBIT Margin | 39.07% |
| FCF Margin | 22.85% |
Dividends & Yields
This stock pays an annual dividend of 3,700.00, which amounts to a dividend yield of 0.96%.
| Dividend Per Share | 3,700.00 |
| Dividend Yield | 0.96% |
| Dividend Growth (YoY) | 236.36% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 23.19% |
| Buyback Yield | -7.09% |
| Shareholder Yield | -6.13% |
| Earnings Yield | 4.88% |
| FCF Yield | 3.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for PharmaResearch is 517,642.86, which is 41.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 517,642.86 |
| Price Target Difference | 41.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 23.29% |
| EPS Growth Forecast (3Y) | 24.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 11.37 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.37 |
| Piotroski F-Score | 6 |